Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  The Journal of Heart and Lung Transplantation

• Publication date

  2006-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.HEALUN.2006.06.010PMID 17045930
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long-term Benefits of Mycophenolate Mofetil after Heart Transplantation

  2005cited by this paper
• It is time to stop ignoring malignancy in heart transplantation: a call to arms.

  2005cited by this paper
• De novo colorectal cancer: five-year survival is markedly lower in transplant recipients compared with the general population.

  2005cited by this paper
• Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients.

  2005cited by this paper
• Incidence of cancer after immunosuppressive treatment for heart transplantation.

  2005cited by this paper
• The Registry of the International Society for Heart and Lung Transplantation: Twentieth Official adult lung and heart-lung transplant report--2003.

  2003cited by this paper
• Use of Rapamycin Slows Progression of Cardiac Transplantation Vasculopathy

  2003cited by this paper
• The registry of the International Society for Heart and Lung Transplantation: twentieth official adult heart transplant report--2003.

  2003cited by this paper
• Malignancy in organ transplantation: heart.

  2002cited by this paper
• Posttransplant malignancies.

  1999cited by this paper
• Are post-transplant lymphomas inevitable?

  1996cited by this paper
• Effect of immunosuppression on preexisting cancers.

  1993cited by this paper
• The effect of immunosuppression on pre-existing cancers.

  1993cited by this paper
• The price of immunotherapy.

  1981cited by this paper
• Malignant lymphomas in transplantation patients.

  1969cited by this paper

• Incidence and risk factors for malignancy after heart transplantation- Analysis of the UNOS Registry.

  2025cites this paper
• Transplant oncology and anti-cancer immunosuppressants

  2025cites this paper
• Azathioprine and risk of non-melanoma skin cancers in organ transplant recipients: a systematic review and update meta-analysis

  2025cites this paper
• Novel association between graft rejection and post-transplant malignancy in solid organ transplantation

  2025cites this paper
• C3 glomerulopathy: advancements in diagnostics and therapeutics.

  2025cites this paper
• Cutaneous Squamous Cell Carcinoma in Immunocompromised Patients

  2025cites this paper
• CCR2-targeted nanoparticles combined with sonodynamic therapy attenuates the acute rejection of heart transplants.

  2025cites this paper
• Frontiers and Controversies in De Novo Gastrointestinal Tumors After Organ Transplantation: Current Progress and Future Directions

  2025cites this paper
• Oncological Complications of Liver Transplantation: A Narrative Review on De Novo and Donor-Transmitted Cancers

  2025cites this paper
• Nanoparticle-based T cell immunoimaging and immunomodulatory for diagnosing and treating transplant rejection

  2024cites this paper
• Cyclic voltammetric research using a poly (yellow PX4R) amplified electrochemical sensor for the simultaneous measurement of mycophenolate mofetil and dopamine

  2024cites this paper
• A review of heart transplant immunosuppressants and nonmelanoma skin cancer

  2023cites this paper
• Facile fabrication of copper oxide modified sensor for determination of Mycophenolate mofetil in biological fluids: A cyclic voltammetric study

  2023cites this paper
• Safety of Immunomodulatory Systemic Therapies Used in the Management of Immune-Related Cutaneous Adverse Events

  2023cites this paper
• Sex Differences in Cardiac Transplantation

  2023cites this paper
• Lung Cancer and Lung Transplantation

  2023cites this paper
• Prevalence of Post-Heart Transplant Malignancies: A Systematic Review and Meta-Analysis.

  2022cites this paper
• Lymphocyte subsets and Langerhans cells in the skin of kidney transplant recipients under three different immunosuppressive regimens

  2022cites this paper
• Cancer among kidney transplant recipients >20 years after transplantation: post-transplant lymphoproliferative disorder remains the most common cancer type in the ultra long-term

  2022cites this paper
• A Review of Systemic Biologics and Local Immunosuppressive Medications in Uveitis

  2022cites this paper
• Clinical, imaging and histopathological features of concurrent malignancies in a dog: Meningoencephalitis of unknown origin and a malignant parotid gland carcinoma

  2022cites this paper
• Post-transplant Lymphoproliferative Disorder Following Cardiac Transplantation

  2022cites this paper
• NONMELANOMA SKIN CANCER IN A HEART TRANSPLANT PATIENT: A CASE REPORT AND REVIEW OF THE LITERATURE

  2022cites this paper
• Risk of malignancy in patients with psoriasis receiving systemic medications: A nested case‐control study

  2022cites this paper
• Higher mycophenolate dosage is associated with an increased risk of squamous cell carcinoma in kidney transplant recipients.

  2022cites this paper
• Сlinical features of malignant tumors against the background of immunosuppressive therapy in heart transplant recipients

  2021cites this paper
• Malignancy following heart transplantation: differences in incidence and prognosis between sexes – a multicenter cohort study

  2021cites this paper
• Skin Cancers and Lung Transplant

  2021cites this paper
• Implications of cancer prior to and after heart transplantation

  2021cites this paper
• Mycophenolic acid and cancer risk in solid organ transplant recipients: Systematic review and meta‐analysis

  2021cites this paper
• Malignancy among adult heart transplant recipients following patient‐tailored dosing of anti‐thymocyte globulin: a retrospective, nested case‐control study of individualized dosing

  2021cites this paper
• EBV Predicts Post-Pediatric Heart Transplant Malignancy; Induction Therapy and Tacrolimus Don't.

  2021cites this paper
• Malignancies in renal transplant recipients: A retrospective single-center descriptive study

  2021cites this paper
• De Novo Malignancy After Liver Transplantation: Risk Assessment, Prevention, and Management-Guidelines From the ILTS-SETH Consensus Conference.

  2021cites this paper
• Особенности течения злокачественных новообразований на фоне иммуносупрессивной терапии у реципиентов сердца

  2021cites this paper
• Malignancy and risk factors in systemic sclerosis patients

  2020cites this paper
• Neoplasia associada ao tratamento das doenças reumáticas

  2020cites this paper
• Therapeutic potential and molecular mechanisms of mycophenolic acid as an anticancer agent.

  2020cites this paper
• Characteristics and outcomes of lung cancer in solid organ transplant recipients.

  2020cites this paper
• Antagomir‐155 Attenuates Acute Cardiac Rejection Using Ultrasound Targeted Microbubbles Destruction

  2020cites this paper
• The relationships between cancer and autoimmune rheumatic diseases.

  2020cites this paper
• Malignancy After Transplant

  2020cites this paper
• Antitumor pharmacotherapy of colorectal cancer in kidney transplant recipients

  2019cites this paper
• Chronic Immunosuppression Medications

  2019cites this paper
• Pretransplant malignancy among lung transplant recipients in the modern era.

  2019cites this paper
• Posttransplant Malignancy.

  2019cites this paper
• Anti-Tumor Potential of IMP Dehydrogenase Inhibitors: A Century-Long Story

  2019cites this paper
• Discontinuing voriconazole induced no completely regression of multiple cutaneous squamous cell carcinoma in a hematopoietic stem cell transplant patient

  2019cites this paper
• Cutaneous squamous cell carcinoma (cSCC) and immunosurveillance – the impact of immunosuppression on frequency of cSCC

  2019cites this paper
• The change of immunosuppressive regimen from calcineurin inhibitors to mammalian target of rapamycin (mTOR) inhibitors and its effect on malignancy following heart transplantation

  2019cites this paper
• Management of Autoimmune Hepatitis Patients Refractory to or Intolerant of Standard Therapies

  2018cites this paper
• A cross-sectional analysis of long-term immunosuppressive regimens after liver transplantation at Asan Medical Center: Increased preference for mycophenolate mofetil

  2018cites this paper
• Advances in autoimmune myasthenia gravis management

  2018cites this paper
• Renal cell cancer after kidney transplantation

  2018cites this paper
• Guidelines of care for the management of cutaneous squamous cell carcinoma.

  2018cites this paper
• Guidelines of care for the management of cutaneous squamous cell carcinoma

  2018cites this paper
• Research gaps in the management and prevention of cutaneous squamous cell carcinoma in organ transplant recipients

  2017cites this paper
• Novel risk factors related to cancer in scleroderma.

  2017cites this paper
• Eighteen Month Interval Growth of Terminal Ileal Primary Adenocarcinoma: A Consideration for Current Screening Guidelines

  2017cites this paper
• Conversion from Calcineurin Inhibitor-Based Immunosuppression to Mycophenolate Mofetil in Monotherapy Reduces Risk of De Novo Malignancies After Liver Transplantation

  2017cites this paper
• Perioperative Management of Cardiac Transplant Recipients Undergoing Noncardiac Surgery: Unique Challenges Created by Advancements in Care

  2017cites this paper
• Risk of early, intermediate, and late rejection following heart transplantation: Trends over the past 25 years and relation to changes in medical management. Tertiary center experience: The Sheba Heart Transplantation Registry

  2017cites this paper
• Tacrolimus Levels Are Not Associated with Risk of Malignancy in Lung Transplant Recipients

  2017cites this paper
• Using a weaning immunosuppression protocol in liver transplantation recipients with hepatocellular carcinoma: a compromise between the risk of recurrence and the risk of rejection?

  2017cites this paper
• Epidemiology and Risk Factors for Cancer After Lung Transplantation.

  2017cites this paper
• Risk factors associated with post–kidney transplant malignancies: an article from the Cancer-Kidney International Network

  2017cites this paper
• Cancer After Kidney Transplantation

  2017cites this paper
• Heart Transplantation and Left Ventricular Assist Devices in Cancer Survivors

  2017cites this paper
• The role of the skin microbiome in atopic dermatitis: a systematic review

  2017cites this paper
• Treatment of New-Onset Psoriasis Post-Kidney Transplant

  2016cites this paper
• EASL Clinical Practice Guidelines: Liver transplantation.

  2016cites this paper
• Does the nature of residual immune function explain the differential risk of non‐melanoma skin cancer development in immunosuppressed organ transplant recipients?

  2016cites this paper
• Malignancies After Heart Transplant.

  2016cites this paper
• Posttransplant Solid Organ Malignancies in Lung Transplant Recipients: A Single-center Experience and Review of the Literature

  2016cites this paper
• De novo malignancy after lung transplantation in Japan

  2016cites this paper
• Daunting but Worthy Goal: Reducing the De Novo Cancer Incidence After Transplantation

  2016cites this paper
• Immune profiling and cancer post transplantation.

  2015cites this paper
• Advances in Our Understanding of Immunosuppression as a Risk Factor for Cutaneous SCC: Evidence for Revision of Immunosuppressive Therapy

  2015cites this paper
• Pretransplant Malignancy as a Risk Factor for Posttransplant Malignancy After Heart Transplantation

  2015cites this paper
• Cutaneous Squamous Cell Carcinomas in Organ Transplant Recipients

  2015cites this paper
• Heart transplantation: review

  2015cites this paper
• Skin cancer evaluation in transplant patients: a physician opinion survey with recommendations

  2015cites this paper
• Renal cell carcinoma with proliferative lupus nephritis

  2015cites this paper
• De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.

  2015cites this paper
• Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation.

  2015cites this paper
• A Review of the Potential Utility of Mycophenolate Mofetil as a Cancer Therapeutic

  2014cites this paper
• State of the art: cardiac transplantation.

  2014cites this paper
• Malignancies after pediatric kidney transplantation: more than PTLD?

  2014cites this paper
• Liver transplantation: immunosuppression and oncology

  2014cites this paper
• Optimal Management of Skin Cancer in Immunosuppressed Patients

  2014cites this paper
• Malignancies After Transplantation and Posttransplant Lymphoproliferative Disorder

  2014cites this paper
• Basic Principles of Transplant Immunology

  2014cites this paper
• Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis.

  2014cites this paper
• Immune monitoring of kidney transplant recipients with post-transplant malignancy.

  2014influential citation
• A case of Nephrotic Syndrome with Brain Tumor - Hooman N et al

  2014cites this paper
• Optimal Management of Skin Cancer in Immunosuppressed

  2014cites this paper
• Long-term immunosuppression and malignancy in thoracic transplantation: where is the balance?

  2014cites this paper
• In-Depth Review Is Newer Safer? Adverse Events Associated with First-Line Therapies for ANCA-Associated Vasculitis and Lupus Nephritis

  2014cites this paper
• Prescription trends of immunosuppressive drugs in post-heart transplant recipients in Taiwan, 2000–2009

  2014cites this paper
• Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy

  2014cites this paper